Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

The amplitude and origin of sea-level variability during the Pliocene epoch.

Grant GR, Naish TR, Dunbar GB, Stocchi P, Kominz MA, Kamp PJJ, Tapia CA, McKay RM, Levy RH, Patterson MO.

Nature. 2019 Oct;574(7777):237-241. doi: 10.1038/s41586-019-1619-z. Epub 2019 Oct 2.

PMID:
31578526
2.

A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV).

Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS.

Epilepsy Res. 2019 Jul;153:66-67. doi: 10.1016/j.eplepsyres.2019.03.002. Epub 2019 Mar 11.

PMID:
30910314
3.

Past, Present, and Future of Drug-Drug Interactions.

Levy RH, Ragueneau-Majlessi I.

Clin Pharmacol Ther. 2019 Jun;105(6):1286-1288. doi: 10.1002/cpt.1349. Epub 2019 Feb 17. No abstract available.

PMID:
30773619
4.

Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I.

Clin Transl Sci. 2019 Jul;12(4):379-387. doi: 10.1111/cts.12623. Epub 2019 Mar 12.

5.

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15. Review.

PMID:
30442649
6.

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development.

Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS.

Epilepsia. 2018 Oct;59(10):1811-1841. doi: 10.1111/epi.14557.

7.

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development.

Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS.

Epilepsia. 2018 Oct;59(10):1842-1866. doi: 10.1111/epi.14555. Erratum in: Epilepsia. 2019 Jan;60(1):187.

8.

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23.

PMID:
29572333
9.

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. Review.

PMID:
28414144
10.

Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Koepp MJ.

Epilepsy Res. 2017 Feb;130:27-36. doi: 10.1016/j.eplepsyres.2017.01.004. Epub 2017 Jan 16.

PMID:
28113141
11.

Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS.

Epilepsia. 2017 Feb;58(2):181-221. doi: 10.1111/epi.13634. Epub 2017 Jan 23. Review.

12.

Dynamic Antarctic ice sheet during the early to mid-Miocene.

Gasson E, DeConto RM, Pollard D, Levy RH.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3459-64. doi: 10.1073/pnas.1516130113. Epub 2016 Feb 22.

13.

The multi-millennial Antarctic commitment to future sea-level rise.

Golledge NR, Kowalewski DE, Naish TR, Levy RH, Fogwill CJ, Gasson EG.

Nature. 2015 Oct 15;526(7573):421-5. doi: 10.1038/nature15706.

PMID:
26469052
14.

Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS.

Epilepsy Res. 2015 Mar;111:85-141. doi: 10.1016/j.eplepsyres.2015.01.001. Epub 2015 Jan 19. Review.

PMID:
25769377
15.

Antarctic contribution to meltwater pulse 1A from reduced Southern Ocean overturning.

Golledge NR, Menviel L, Carter L, Fogwill CJ, England MH, Cortese G, Levy RH.

Nat Commun. 2014 Sep 29;5:5107. doi: 10.1038/ncomms6107.

PMID:
25263015
16.

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS.

Epilepsy Res. 2013 Jan;103(1):2-30. doi: 10.1016/j.eplepsyres.2012.10.001. Epub 2012 Dec 4. Review.

17.

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I.

Chem Res Toxicol. 2012 Nov 19;25(11):2285-300. doi: 10.1021/tx300192g. Epub 2012 Sep 27. Review.

18.

Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.

Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, Okulicz JF, Clifford DB, Hachad H, Levy RH; Quality Standards Subcommittee Of The American Academy Of Neurology; Ad Hoc Task Force Of The Commission On Therapeutic Strategies Of The International League Against Epilepsy.

Epilepsia. 2012 Jan;53(1):207-14. doi: 10.1111/j.1528-1167.2011.03335.x. Review.

19.

Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, Okulicz JF, Clifford DB, Hachad H, Levy RH; Quality Standards Subcommittee of the American Academy of Neurology; Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Neurology. 2012 Jan 10;78(2):139-45. doi: 10.1212/WNL.0b013e31823efcf8. Epub 2012 Jan 4. Review.

20.

e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure.

Hachad H, Overby CL, Argon S, Yeung CK, Ragueneau-Majlessi I, Levy RH.

Hum Genomics. 2011 Jul;5(5):506-15. Review.

21.

Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N.

Clin Pharmacol Ther. 2011 Jan;89(1):105-13. doi: 10.1038/clpt.2010.252. Epub 2010 Dec 1. Erratum in: Clin Pharmacol Ther. 2011 Mar;89(3):468.

22.
23.

Nefopam pharmacokinetics in patients with end-stage renal disease.

Mimoz O, Chauvet S, Grégoire N, Marchand S, Le Guern ME, Saleh A, Couet W, Debaene B, Levy RH.

Anesth Analg. 2010 Nov;111(5):1146-53. doi: 10.1213/ANE.0b013e3181f33488.

PMID:
20971961
24.

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS.

Epilepsy Res. 2010 Dec;92(2-3):89-124. doi: 10.1016/j.eplepsyres.2010.09.001. Review.

PMID:
20970964
25.

Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

Zhang H, Ragueneau-Majlessi I, Levy RH.

Drug Metab Lett. 2009 Dec;3(4):287-9.

PMID:
19995331
26.

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM.

J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196.

PMID:
19246732
27.
28.

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS.

Epilepsy Res. 2009 Jan;83(1):1-43. doi: 10.1016/j.eplepsyres.2008.09.005. Epub 2008 Nov 12.

PMID:
19008076
29.

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH.

Curr Drug Metab. 2007 Dec;8(8):810-4.

PMID:
18220561
30.

Risk and predictability of drug interactions in the elderly.

Levy RH, Collins C.

Int Rev Neurobiol. 2007;81:235-51. Review.

PMID:
17433928
31.

Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).

Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T.

Epilepsy Res. 2007 Jan;73(1):1-52. Epub 2006 Dec 8.

PMID:
17158031
32.

Pharmacological and clinical aspects of antiepileptic drug use in the elderly.

Perucca E, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, Levy RH, Pugh MJ.

Epilepsy Res. 2006 Jan;68 Suppl 1:S49-63. Epub 2005 Oct 3. Review.

PMID:
16207524
33.

A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.

Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M.

Epilepsia. 2005 Jul;46(7):1046-54.

34.

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS.

Clin Pharmacokinet. 2005;44(5):517-23.

PMID:
15871637
35.

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ.

Ther Drug Monit. 2005 Apr;27(2):193-8.

PMID:
15795651
36.

Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.

Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M.

Epilepsia. 2005 Mar;46(3):378-84.

37.

Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).

Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T.

Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48.

PMID:
15570674
38.

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.

Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JS.

Epilepsy Res. 2004 Nov;62(1):1-11.

PMID:
15519127
39.

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J, Pan WJ.

J Clin Pharmacol. 2004 Nov;44(11):1230-4.

PMID:
15496640
40.

Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.

Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M.

Epilepsy Res. 2004 Jan;58(1):1-12.

PMID:
15066669
41.
42.

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.

Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF.

Drug Metab Dispos. 2003 Aug;31(8):1043-8.

PMID:
12867493
43.

Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.

Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, Maryanoff BE, Bialer M.

Ther Drug Monit. 2003 Jun;25(3):314-22.

PMID:
12766560
44.

Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH.

Drug Metab Dispos. 2003 May;31(5):565-71.

PMID:
12695344
45.

Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.

Chawla J, Le Guern ME, Alquier C, Kalhorn TF, Levy RH.

Ther Drug Monit. 2003 Apr;25(2):203-10.

PMID:
12657915
46.

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

Lakehal F, Wurden CJ, Kalhorn TF, Levy RH.

Epilepsy Res. 2002 Dec;52(2):79-83.

PMID:
12458024
47.

Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).

Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E.

Epilepsy Res. 2002 Sep;51(1-2):31-71.

PMID:
12350382
48.

Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.

Yao C, Levy RH.

J Pharm Sci. 2002 Sep;91(9):1923-35. Review.

PMID:
12210040
49.

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.

Ragueneau-Majlessi I, Levy RH, Janik F.

Epilepsia. 2002 Jul;43(7):697-702.

50.

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.

Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.

Epilepsia. 2002 Jul;43(7):691-6. Erratum in: Epilepsia 2002 Oct;43(10):1273.

Supplemental Content

Support Center